Reporting adverse incidents: insulin pumps and meter systems

AI Summary

The UK Medicines and Healthcare products Regulatory Agency (MHRA) issued this critical guidance to assist manufacturers in reporting adverse incidents related to insulin infusion pumps and integrated meter systems. Operating under the UK's Medical Device Vigilance System and broader post-market surveillance framework, the document outlines the necessary protocols for maintaining device safety. Although this is a general regulatory document rather than a report on a specific company or inspection date, it serves as the benchmark for compliance for all manufacturers in this sector. The main issues addressed include the failure to report device malfunctions, software glitches affecting insulin delivery, and hardware defects that could cause patient harm. Manufacturers are required to take specific actions, including the implementation of rigorous post-market surveillance programs and the timely submission of incident reports to the MHRA. Furthermore, the guidance mandates that manufacturers must conduct thorough investigations into any reported failures and issue Field Safety Corrective Actions when necessary. By following these requirements, manufacturers ensure that integrated systems function correctly and that patient safety is prioritized through transparent reporting. This guidance must be applied alongside existing post-market surveillance standards to ensure a comprehensive approach to device life-cycle management and regulatory adherence within the healthcare technology industry.